Howard S Hochster, MD

Professor of Medicine (Medical Oncology); Associate Director for Clinical Sciences, Yale Cancer Center; Clinical Program Leader, Gastrointestinal Cancers Program, Smilow Cancer Hospital; Clinical Research Program Leader, Gastrointestinal Cancers Program, Yale Cancer Center

Clinical Interests

  • Esophageal Neoplasms
  • Gastrointestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms
  • Colorectal Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Gastrointestinal Cancer Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine

  • Internal Medicine AB of Internal Medicine (1983)

  • Hematology (Internal Medicine) AB of Internal Medicine (1986)

Clinical Trials

Conditions Study Title
Liver Phase I/II Study of MEDI4736+Tremelimumab or Monotherapy in Subjects with Hepatocellular Carcinoma
Stomach Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment
Esophagus NCI 9824: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
Stomach A Phase I Study of TAS-102 + Irinotecan and Bevacizumab
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Other Digestive Organ, Pancreas E2211: Phase II study of Temozolomide or Temozolomide + Capecitabine in Patients w Pancreatic Tumors
Pancreas Phase II Gemcitabine & Nab-paclitaxel +/- NPC-1C in metastatic or locally advanced pancreatic cancer
Other Digestive Organ Phase Ib study of DKN-01 plus gemcitabine and cisplatin in pts biliary system or gallbladder cancer
Other Digestive Organ, Stomach Phase 3 study of Ramucirumab in combination with Capecitabine & Cisplatin in pts with stomach cancer
Breast - Female, Breast - Male, Lung, Pancreas Nivolumab in combination with nab-paclitaxel based therapy in Panc, NSCLC, and mBC
Pancreas Olaparib in gBRCA Mutated Pancreatic Cancer pts Not Progressed on 1st Line Platinum-Based Chemo
Esophagus, Other Digestive Organ Phase 1 study of DKN-01 plus Paclitaxel in pts with relapsed or refractory esophageal or GEJ cancer
Colon Pilot Study of Xolair in Reducing Oxaliplatin-induced HSR
Colon, Rectum S1406: Phase II study of irinotecan and cetuximab +/- vemurafenib in BRAF mutant metastatic CRC
Pancreas nab-paclitaxel plus gemcitabine in subjects with locally advanced pancreatic cancer
Pancreas Phase 3 study of adjuvant nab-Paclitaxel + gemcitabine vs. gemcitabine in resected pancreatic cancer
Pancreas S1313: Phase Ib/II Study of mFOLFIRINOX +PEGPH20 vs. mFOLFIRINOX in Met. Pancreatic Adenocarcinoma
Colon S0820: Preventing Adenomas of the Colon with Eflornithine and Sulindac
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Pancreas Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer

Edit this profile